Article type
Abstract
Background:
Inherited metabolic diseases (IMDs) may have considerable implications for patients and their families. Despite their individual rarity, covering a spectrum of over 1800 distinct diseases, the diseases collectively exert a significant impact, with often lifelong disabilities. Some diseases have specific treatments available, but most lack targeted therapies. Delayed diagnosis of IMDs may lead to irreversible organ damage.
The United for Metabolic Diseases (UMD) consortium was established to address this need by synergizing efforts of patients, families, clinicians, researchers, and fundraisers to catalyze research with translation into the best possible care.
Aim:
To generate a translational knowledge agenda, which identifies and prioritizes research questions, directly relevant to patient care or for IMD patients and their families.
Methods and Results:
Following a process established by the Knowledge Institute of the Dutch Association of Medical Specialists, we generated a comprehensive translational knowledge agenda for IMDs. A multidisciplinary steering committee composed of 12 metabolic experts, representing laboratory specialists, metabolic researchers, pediatricians, internists, pediatric neurologists, dieticians, nurse specialists, and patient organizations, collected research questions through an online questionnaire using snowballing. The 462 proposed questions underwent rigorous assessment, categorization, and prioritization during a meeting attended by 22 representatives of all stakeholder groups. The resulting top 10 research questions cover multiple themes, including prediction of disease progression, development of novel tools, mechanistic insights, improved diagnostics, therapeutic integration of multi-omics techniques, assessment of impact on daily life, expanding treatment avenues, optimal study designs, effect of lifestyle interventions, and data utilization using FAIR principles. Patient involvement at every stage ensured that their perspectives were integrated, solidifying patient-centeredness.
Discussion:
Challenges in prioritization arose from the diverse nature of the field, which prompted us to leave out questions dealing with single rare diseases. Nonetheless, this collective endeavor reflects the collaborative spirit needed for rare disease research. This knowledge agenda will not only guide funding directions and applications but will also boost interdisciplinary collaboration to push the field of IMDs research forward in a renewed UMD consortium. Patient engagement, transparency, and a comprehensive approach make this knowledge agenda a pivotal step toward addressing the pressing research needs and priorities in this domain.
Inherited metabolic diseases (IMDs) may have considerable implications for patients and their families. Despite their individual rarity, covering a spectrum of over 1800 distinct diseases, the diseases collectively exert a significant impact, with often lifelong disabilities. Some diseases have specific treatments available, but most lack targeted therapies. Delayed diagnosis of IMDs may lead to irreversible organ damage.
The United for Metabolic Diseases (UMD) consortium was established to address this need by synergizing efforts of patients, families, clinicians, researchers, and fundraisers to catalyze research with translation into the best possible care.
Aim:
To generate a translational knowledge agenda, which identifies and prioritizes research questions, directly relevant to patient care or for IMD patients and their families.
Methods and Results:
Following a process established by the Knowledge Institute of the Dutch Association of Medical Specialists, we generated a comprehensive translational knowledge agenda for IMDs. A multidisciplinary steering committee composed of 12 metabolic experts, representing laboratory specialists, metabolic researchers, pediatricians, internists, pediatric neurologists, dieticians, nurse specialists, and patient organizations, collected research questions through an online questionnaire using snowballing. The 462 proposed questions underwent rigorous assessment, categorization, and prioritization during a meeting attended by 22 representatives of all stakeholder groups. The resulting top 10 research questions cover multiple themes, including prediction of disease progression, development of novel tools, mechanistic insights, improved diagnostics, therapeutic integration of multi-omics techniques, assessment of impact on daily life, expanding treatment avenues, optimal study designs, effect of lifestyle interventions, and data utilization using FAIR principles. Patient involvement at every stage ensured that their perspectives were integrated, solidifying patient-centeredness.
Discussion:
Challenges in prioritization arose from the diverse nature of the field, which prompted us to leave out questions dealing with single rare diseases. Nonetheless, this collective endeavor reflects the collaborative spirit needed for rare disease research. This knowledge agenda will not only guide funding directions and applications but will also boost interdisciplinary collaboration to push the field of IMDs research forward in a renewed UMD consortium. Patient engagement, transparency, and a comprehensive approach make this knowledge agenda a pivotal step toward addressing the pressing research needs and priorities in this domain.